

The Manager Company Announcements Office ASX Limited

LBT GRANTED PATENT IN JAPAN FOR CORE APAS® TECHNOLOGY

Adelaide, 19 May 2016: Australian medical technology company LBT Innovations Limited (ASX: LBT) has received confirmation that the Japan Patent Office has granted the company's application for a Japanese patent protecting the image capture technology of its Automated Plate Assessment System (APAS®).

APAS® is a novel technology that has successfully been shown to assess microbiology samples for the presence of disease-causing bacteria, with significant implications for laboratory efficiency.

The patent relates to patent application no. 2013-555706, which covers the image capture and lighting apparatus of the APAS® technology. The patent provides protection of this intellectual property throughout Japan for the next 16 years.

The Japanese patent follows three successful applications for United States patents covering the APAS® image capture and lighting apparatus, the key systems and analytical software of APAS®, and a novel method used to 'colour calibrate' images captured by APAS®.

These three patents all provide for 20 years of patent protection, and are part of a portfolio of four inventions related to APAS, for which LBT initiated intellectual property protection in 2011.

The first APAS instrument, the APAS® Independence, was unveiled at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam last month.

The APAS® Independence is an automated culture plate reader and sorter that integrates APAS® with high-speed robotic plate-handling equipment in a world-first plate-handling solution. The instrument was unveiled by Clever Culture Systems AG, the joint venture established by LBT and its 50-50 development partner, Hettich AG Switzerland.

- ENDS -

About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: MicroStreak®, which provides automation of culture plate streaking, and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. Based on LBT's innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture with Hettich AG Switzerland to drive the commercialisation of APAS products. LBT also has a third product in development, WoundVue™, a proposed automation solution to assist in the management of chronic wounds. For more information, see www.lbtinnovations.com

About Clever Culture Systems

Clever Culture Systems ÅG is the Zurich-based joint venture between LBT Innovations and Hettich AG Switzerland, a world-class laboratory equipment manufacturer based in Switzerland. Clever Culture Systems brings the complementary skills and expertise of both parties to bear in an area of laboratory medicine, microbiology, which is in need of automation.

CONTACTS

LBT Innovations	Clever Culture Systems	Media Relations
Lusia Guthrie, CEO Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Peter Bradley, General Manager Tel: +61 (0)8 8227 1555 E: pmb@cleverculturesystems.com	Dean Felton, Monsoon Communications Tel: +61 (0)3 9620 3333 Mob: +61 (0) 411 698 499 E: deanf@monsoon.com.au